Clinical Trial: T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer, an Exploratory Non-intervention Study.

U.S., May 13 -- ClinicalTrials.gov registry received information related to the study (NCT07581496) titled 'T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer, an Exploratory Non-intervention Study.' on May 05.

Brief Summary: T1G3 bladder cancer is a heterogeneous disease with a high risk of disease persistence after the first TUR-B, understaging, disease progression, bladder removal, and mortality.

Current risk stratification is insufficient and needs improvement. Ct-DNA could identify patients with disease persistence, progression and could monitor and tailor therapy. It might improve patient risk stratification, avoiding under- and overtreatment, reducing morbidity and mortality.

Primary objective is to...